WO2008042773A3 - Unitary pharmaceutical composition, method, and kit for the treatment or prevention of metabolic or endocrine disorders - Google Patents

Unitary pharmaceutical composition, method, and kit for the treatment or prevention of metabolic or endocrine disorders Download PDF

Info

Publication number
WO2008042773A3
WO2008042773A3 PCT/US2007/079889 US2007079889W WO2008042773A3 WO 2008042773 A3 WO2008042773 A3 WO 2008042773A3 US 2007079889 W US2007079889 W US 2007079889W WO 2008042773 A3 WO2008042773 A3 WO 2008042773A3
Authority
WO
WIPO (PCT)
Prior art keywords
treatment
prevention
kit
pharmaceutical composition
metabolic
Prior art date
Application number
PCT/US2007/079889
Other languages
French (fr)
Other versions
WO2008042773A2 (en
Inventor
Michael Schwartz
Iv George Mitchell Grass
Original Assignee
Pdxrx Inc
Michael Schwartz
Iv George Mitchell Grass
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pdxrx Inc, Michael Schwartz, Iv George Mitchell Grass filed Critical Pdxrx Inc
Publication of WO2008042773A2 publication Critical patent/WO2008042773A2/en
Publication of WO2008042773A3 publication Critical patent/WO2008042773A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Unitary dosage form pharmaceutical composition(s), pharmaceutical kit(s), and method(s) of treatment comprising sufficient amounts of at least one biguanide, at least one first pharmaceutical agent, and optionally at least one HmG-CoA reductase inhibitor, or at least one fibrate, or at least one angiotensin converting enzyme inhibitor, or at least one angiotensin II receptor blocker, or at least one second pharmaceutical agent, or combinations thereof, for the treatment or prevention of diabetic, cardiac, or endocrine outcomes associated with obesity as well as various metabolic or endocrine disorders or combinations thereof. In a preferred embodiment, the biguanide is metformin, stereoisomers thereof, derivatives thereof, or metabolites thereof, and the first pharmaceutical agent is sibutramine, rimonabant, derivatives thereof, stereoisomers thereof, or metabolites thereof. Magnesium may also optionally be included.
PCT/US2007/079889 2006-09-29 2007-09-28 Unitary pharmaceutical composition, method, and kit for the treatment or prevention of metabolic or endocrine disorders WO2008042773A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US84815006P 2006-09-29 2006-09-29
US60/848,150 2006-09-29

Publications (2)

Publication Number Publication Date
WO2008042773A2 WO2008042773A2 (en) 2008-04-10
WO2008042773A3 true WO2008042773A3 (en) 2008-08-28

Family

ID=39269115

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/079889 WO2008042773A2 (en) 2006-09-29 2007-09-28 Unitary pharmaceutical composition, method, and kit for the treatment or prevention of metabolic or endocrine disorders

Country Status (1)

Country Link
WO (1) WO2008042773A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010151503A2 (en) * 2009-06-25 2010-12-29 Metabolous Pharmaceuticals, Inc. Combination therapies for the treatment of obesity
WO2010151565A2 (en) * 2009-06-26 2010-12-29 Metabolous Pharmaceuticals, Inc. Combination therapies for the treatment of obesity
GB202008699D0 (en) * 2020-06-09 2020-07-22 Healx Ltd Treatment

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5658955A (en) * 1994-11-01 1997-08-19 Hitzig; Pietr Combined use of dopamine and serotonin agonists in the treatment of immune disorders
WO2000032178A2 (en) * 1998-12-02 2000-06-08 Peter Sterling Mueller Use of siburamine for the treatment of disorders of the central nervous system secondary to organic impairments
US6441038B1 (en) * 1999-10-12 2002-08-27 Laxdale Limited Treatment of fatigue, head injury and stroke
US20030187074A1 (en) * 2002-03-04 2003-10-02 Javed Hussain Oral compositions for treatment of diabetes

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5658955A (en) * 1994-11-01 1997-08-19 Hitzig; Pietr Combined use of dopamine and serotonin agonists in the treatment of immune disorders
WO2000032178A2 (en) * 1998-12-02 2000-06-08 Peter Sterling Mueller Use of siburamine for the treatment of disorders of the central nervous system secondary to organic impairments
US6441038B1 (en) * 1999-10-12 2002-08-27 Laxdale Limited Treatment of fatigue, head injury and stroke
US20030187074A1 (en) * 2002-03-04 2003-10-02 Javed Hussain Oral compositions for treatment of diabetes

Also Published As

Publication number Publication date
WO2008042773A2 (en) 2008-04-10

Similar Documents

Publication Publication Date Title
WO2006088748A3 (en) Method for treating obesity
WO2010029089A3 (en) Combination therapy for the treatment of diabetes and related conditions
EP1756074A4 (en) 1,2,4-oxadiazole derivatives as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
WO2005084654A3 (en) Methods and compositions for treating or preventing psychiatric disorders with cox-2 inhibitors alone and in combination with antidepressant agents
WO2007120702A3 (en) Use of gpr119 receptor agonists for increasing bone mass and for treating osteoporosis, and combination therapy relating thereto
WO2007078726A3 (en) Pharmaceutical compositions of combinations of dipeptidyl peptidase-4 inhibitors with metformin
WO2005070462A3 (en) Compositions comprising (s)-amlodipine and an angiotensin receptor blocker and methods of their use
EP1756106A4 (en) Cyclohexylalanine derivatives as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
AP2373A (en) Enantiomerically pure aminoheteroaryl compounds asprotein kinase inhibitors.
EP1761532A4 (en) Aminocyclohexanes as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
WO2009117421A3 (en) Heterocyclic modulators of gpr119 for treatment of disease
WO2009024429A3 (en) Preventing and/or treating metabolic disorders by modulating the amount of enterobacteria
WO2010092123A8 (en) Sglt-2 inhibitor for treating type 1 diabetes mellitus, type 2 diabetes mellitus, impaired glucose tolerance or hyperglycemia
EP1582105A4 (en) Method of inhibiting water content variation of composition and use thereof
GEP20135962B (en) Pharmaceutical composition comprising sglt2 inhibitor, dpp-iv inhibitor, and optionally further antidiabetic agent; and usage thereof
WO2007127763A3 (en) Inhibitors of 11-beta-hydroxysteroid dehydrogenase 1
WO2007077560A3 (en) Cryoprotective compositions and methods of using same
WO2006105127A8 (en) Hydroxysteroid dehydrogenase inhibitors
WO2007124254A3 (en) Cyclohexylpyrazole-lactam derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase 1
WO2008031551A3 (en) Non-neuroendocrine cancer therapy
CL2012002522A1 (en) Pharmaceutical composition comprising a dpp iv inhibitor compound with an amino group or a salt thereof, a first diluent, a second diluent, a binder, a disintegrant and a lubricant, useful in the treatment of diabetes mellitus.
WO2006076231A8 (en) Combination therapy for the treatment of diabetes and conditions related thereto and for the treatment of conditions ameliorated by increasing a blood glp-1 level
EP1924293A4 (en) Composition and method for prevention and treatment of type i diabetes
WO2007089445A3 (en) Ang2 and vegf inhibitor combinations
WO2007109135A3 (en) Neuromedin u receptor agonists and uses thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07843483

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 07843483

Country of ref document: EP

Kind code of ref document: A2